In this study, we identified BAP1 regulates tumor immune microenvironment and the sensitivity to ICB treatment in a PD-L1 independent manner, and demonstrated a potential effective strategy to overcome the un-responsiveness to ICB therapy in BAP1 deficient pancreatic cancer [37]. The gene discussed is BAP1; the disease is pancreatic neoplasm.